Skip to content

A multi-center, open-label, randomized controlled clinical trial study on the treatment of Delta novel coronavirus pneumonia (COVID-19) based on ''three-party'' syndrome differentiation and treatment

A multi-center, open-label, randomized controlled clinical trial study on the treatment of Delta novel coronavirus pneumonia (COVID-19) based on ''three-party'' syndrome differentiation and treatment

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100049665
Enrollment
Unknown
Registered
2021-08-08
Start date
2021-08-07
Completion date
Unknown
Last updated
2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Delta Novel Coronavirus Pneumonia

Interventions

Sponsors

Affiliated Hospital of Nanjing University of Chinese Medicine (Jiangsu Province Hospital of Chinese Medicine)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients with mild and common new coronavirus pneumonia who meet the diagnostic criteria of the ''New Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial Version 8)'', with onset within 7 days. 2. Informed consent, volunteer experiment. 3. The process of obtaining informed consent should comply with GCP regulations.

Exclusion criteria

Exclusion criteria: 1. Aged <18 years; 2. Combined with serious primary heart, lung, liver, kidney, blood or diseases affecting their survival; 3. Creatinine and ALT/AST exceed 1.5 times the upper limit of normal; 4. Patients with mental illness, limited cognitive ability and disabled patients prescribed by law; 5. Pregnant or lactating patients; 6. Patients within 3 months or participating in clinical trials of other drugs.

Design outcomes

Primary

MeasureTime frame
10 day rate of mild and general type conversed to severe type;

Countries

China

Contacts

Public ContactZhu Jia

Jiangsu Province Hospital of Chinese Medicine

jsnjzj@163.com+86 13813988992

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026